Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21132657 | 1.00 | ALDH1A1 (0.43) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL24681676 | 1.00 | ALDH1A1 (0.43) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL29980474 | 0.85 | GAA (0.48) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL25020656 | 0.83 | ALDH1A1 (0.38) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL2227563 | 0.77 | HPGD (0.46) | ALDH1A1POLBGAAKDM4ESMN1; SMN2 | |
| SCHEMBL14831804 | 0.77 | PDK2 (0.41) | NPC1 | |
| SCHEMBL29283156 | 0.73 | GAA (0.66) | ALDH1A1GAAKDM4ESMN1; SMN2TDP1 | |
| SCHEMBL23326600 | 0.71 | USP30 (0.38) | POLBSMN1; SMN2LMNA | |
| SCHEMBL21132553 | 0.71 | HPGD (0.56) | ALDH1A1POLBGAAKDM4EHPGD | |
| SCHEMBL29723381 | 0.71 | HPGD (0.56) | ALDH1A1POLBGAAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-01-14 | — | — | US | disclosed |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-11-10 | — | — | US | disclosed |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009588-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1453/4885POLB 4334/4885GAA 3531/4885 |
| US-11814380-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1272/4885POLB 4404/4885GAA 3390/4885 |
| US-20190194192-A1 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOST, SOS2 | ALDH1A1 1511/4885POLB 4281/4885GAA 3543/4885 |
| US-10829487-B2 | Benzylamino substituted pyridopyrimidinones and derivatives as SOS1 inhibitors | SOS1, SOST, BMP1 | ALDH1A1 1301/4885POLB 4358/4885GAA 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.